摘要
目的分析替雷利珠单抗联合安罗替尼治疗晚期肺鳞状细胞癌(PSCC)的疗效。方法选取晚期PSCC患者,按照治疗方法分为研究组(替雷利珠单抗联合安罗替尼)和对照组(安罗替尼),采用基线资料倾向性评分匹配法,按1∶1两组配对成功62对患者。比较两组临床疗效、肿瘤标志物、不良反应和生活质量。结果研究组客观缓解率和疾病控制率高于对照组(P<0.05)。两组不良反应发生率比较差异无显著性(P>0.05)。与治疗前比较,治疗后两组CYFRA21-1和SCCA表达水平下降,躯体功能、社会功能、角色功能及情绪功能评分均提高,且治疗后研究组改善较对照组更为显著(P<0.05)。结论替雷利珠单抗联合安罗替尼治疗晚期PSCC效果较好,且安全性高。
Aim To evaluate the efficacy of tirellizumab combined with antirotinib in the treatment of advanced lung squamous cell carcinoma(PSCC).Methods Patients with advanced PSCC were selected and divided into study group(tirellizumab combined with anlotinib)and control group(anlotinib)according to treatment methods.62 pairs of patients were successfully matched at the ratio of 1∶1 according by using baseline data propensity score matching method.The clinical efficacy,tumor markers,adverse reactions and quality of life were compared between the two groups.Results The objective remission rate and disease control rate of study group was higher than that of control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Compared with the levels before treatment,the expression levels of CYFRA21-1 and SCCA in the two groups were decreased after treatment,whereas the scores of physical function,social function,role function and emotional function were increased,and the improvement in the study group after treatment was more significant than that in the control group(P<0.05).Conclusion Tirellizumab combined with anlotinib is effective and safe in the treatment of advanced PSCC.
作者
刘伟
龙瑜琴
赵荣
LIU Wei;LONG Yuqin;ZHAO Rong(Respiratory and Critical Care Medicine Department,the Affiliated Dazu Hospital of Chongqing Medical University,Chongqing 402360,China;Radiology Department,the Affiliated Dazu Hospital of Chongqing Medical University,Chongqing 402360,China)
出处
《中南医学科学杂志》
2025年第1期114-117,共4页
Medical Science Journal of Central South China
基金
重庆市科卫联合医学科研项目(2020FYYX053)。
